Genfit : Unsurprising numbers
>Cash position of € 62m at end-June - Genfit turned in solid half-year results, with a cash position of € 61.6m at end-June. This is strengthened by the payment, in Q3, of € 48.7m for the initial sales of Ipsen’s Iqirvo in the US. Moreover, Genfit is set to receive € 26.5m over the next few months from the regulatory approval and launch of the drug in Europe. Based on this cash position, the group has financial visibility out to end-2025. The operating incom...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.